View Future GrowthAdvent Pharma 過去の業績過去 基準チェック /26Advent Pharmaの収益は年間平均-14.5%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間2.2% 0.07%割合で 減少しています。 Advent Pharmaの自己資本利益率は3.1%であり、純利益率は10.5%です。主要情報-14.48%収益成長率-14.43%EPS成長率Pharmaceuticals 業界の成長11.00%収益成長率-0.067%株主資本利益率3.08%ネット・マージン10.48%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026お知らせ • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025お知らせ • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026お知らせ • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.お知らせ • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladeshお知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025お知らせ • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025Reported Earnings • Nov 15Full year 2024 earnings released: EPS: ৳0.90 (vs ৳1.06 in FY 2023)Full year 2024 results: EPS: ৳0.90 (down from ৳1.06 in FY 2023). Revenue: ৳571.7m (up 2.4% from FY 2023). Net income: ৳84.0m (down 15% from FY 2023). Profit margin: 15% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 13% per year.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.10 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 December 2024. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.6%).お知らせ • Nov 11Advent Pharma Ltd. to Report Q1, 2025 Results on Nov 13, 2024Advent Pharma Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 06New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 138% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (138% cash payout ratio). Revenue is less than US$5m (৳569m revenue, or US$4.7m). Market cap is less than US$100m (৳1.65b market cap, or US$13.8m).Declared Dividend • Oct 31Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 21st November 2024 Payment date: 22nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (20% earnings payout ratio) but not covered by cash flows (138% cash payout ratio). The dividend has increased by an average of 5.2% per year over the past 6 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.お知らせ • Oct 30Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024, at 12:00 Central Asia Standard Time.Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳19.80, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 31% over the past three years.お知らせ • Oct 21Advent Pharma Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Advent Pharma Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.90, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.Buy Or Sell Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ৳19.90. The fair value is estimated to be ৳25.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.お知らせ • Sep 03Advent Pharma Ltd. Appoints Md. Delwar Hossen as Company SecretaryAdvent Pharma Ltd. announced that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company.Buy Or Sell Opportunity • Jun 13Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ৳25.40. The fair value is estimated to be ৳21.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.New Risk • May 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳564m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 12% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳564m revenue, or US$4.8m). Market cap is less than US$100m (৳2.81b market cap, or US$24.0m).Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳26.90, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 48% over the past three years.お知らせ • Apr 30Advent Pharma Ltd. to Report Q3, 2024 Results on Apr 29, 2024Advent Pharma Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: ৳0.27 (vs ৳0.28 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.27 (down from ৳0.28 in 2Q 2023). Revenue: ৳137.1m (up 4.1% from 2Q 2023). Net income: ৳25.1m (down 5.5% from 2Q 2023). Profit margin: 18% (down from 20% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.お知らせ • Jan 24Advent Pharma Ltd. to Report Q2, 2023 Results on Jan 30, 2024Advent Pharma Ltd. announced that they will report Q2, 2023 results on Jan 30, 2024New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (৳2.29b market cap, or US$20.9m).Valuation Update With 7 Day Price Move • Dec 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳27.00, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 24% over the past three years.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per share at 0.9% yieldEligible shareholders must have bought the stock before 21 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).お知らせ • Nov 13Advent Pharma Ltd. to Report Q1, 2024 Results on Nov 14, 2023Advent Pharma Ltd. announced that they will report Q1, 2024 results on Nov 14, 2023お知らせ • Oct 31+ 1 more updateAdvent Pharma Ltd., Annual General Meeting, Dec 28, 2023Advent Pharma Ltd., Annual General Meeting, Dec 28, 2023, at 12:00 Bangladesh Standard Time.お知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2023 Results on Oct 28, 2023Advent Pharma Ltd. announced that they will report fiscal year 2023 results on Oct 28, 2023Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.29 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.28 (down from ৳0.29 in 3Q 2022). Revenue: ৳149.4m (up 3.0% from 3Q 2022). Net income: ৳26.5m (down 3.4% from 3Q 2022). Profit margin: 18% (down from 19% in 3Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.28 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.28 (up from ৳0.28 in 2Q 2022). Revenue: ৳131.7m (up 4.4% from 2Q 2022). Net income: ৳26.6m (up 2.2% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳23.30, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 41% over the past three years.Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 01Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Advent Pharma Ltd. has recommended 2% cash dividend only for general shareholders (Excluding Sponsors and Directors) for the year ended June 30, 2022.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳24.50, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Aug 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 11% over the past three years.Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 9.3% over the past three years.Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 16 January 2022. Trailing yield: 0.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳28.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 3.2% over the past three years.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ৳32.20, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.Reported Earnings • Sep 10Third quarter 2021 earnings released: EPS ৳0.23 (vs ৳0.23 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ৳125.2m (down 14% from 3Q 2020). Net income: ৳20.8m (up 1.4% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳26.30, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 2.9% over the past three years.Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳23.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.Is New 90 Day High Low • Jan 07New 90-day high: ৳23.70The company is up 14% from its price of ৳20.73 on 08 October 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 20% over the same period.Reported Earnings • Dec 24Third quarter 2020 earnings released: EPS ৳0.23The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳144.8m (down 9.2% from 3Q 2019). Net income: ৳20.5m (down 54% from 3Q 2019). Profit margin: 14% (down from 28% in 3Q 2019). The decrease in margin was primarily driven by lower revenue.お知らせ • Jul 07Advent Pharma Ltd. to Report Q3, 2020 Results on Jun 24, 2020Advent Pharma Ltd. announced that they will report Q3, 2020 results on Jun 24, 2020収支内訳Advent Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DSE:ADVENT 収益、費用、利益 ( )BDT Millions日付収益収益G+A経費研究開発費31 Mar 264584867031 Dec 255165778030 Sep 255186683030 Jun 255006780031 Mar 254794982031 Dec 245065883030 Sep 245226783030 Jun 245728486031 Mar 245699291031 Dec 235649292030 Sep 235589390030 Jun 235589988031 Mar 235529887031 Dec 225489988030 Sep 225429987030 Jun 225309887031 Mar 2252611092031 Dec 2150710488030 Sep 2150411683030 Jun 2150411479031 Mar 214459461031 Dec 204649462030 Sep 204929867030 Jun 2053411771031 Mar 2058914076031 Dec 1960416570030 Sep 1961916971030 Jun 1960215871031 Mar 1960617280031 Dec 1854114481030 Sep 1845611277030 Jun 183968776031 Mar 183576460030 Sep 173185754030 Jun 172854950030 Jun 1622828470質の高い収益: ADVENTは 高品質の収益 を持っています。利益率の向上: ADVENTの現在の純利益率 (10.5%)は、昨年(10.2%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ADVENTの収益は過去 5 年間で年間14.5%減少しました。成長の加速: ADVENTは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: ADVENTは過去 1 年間で収益成長率がマイナス ( -1.3% ) となったため、 Pharmaceuticals業界平均 ( 8.6% ) と比較することが困難です。株主資本利益率高いROE: ADVENTの 自己資本利益率 ( 3.1% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:46終値2026/05/21 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Advent Pharma Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026
お知らせ • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025
お知らせ • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 29Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026
お知らせ • Jan 26Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 10Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 28Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.
お知らせ • Oct 27Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh
お知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025
お知らせ • Apr 28Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 27Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
Reported Earnings • Nov 15Full year 2024 earnings released: EPS: ৳0.90 (vs ৳1.06 in FY 2023)Full year 2024 results: EPS: ৳0.90 (down from ৳1.06 in FY 2023). Revenue: ৳571.7m (up 2.4% from FY 2023). Net income: ৳84.0m (down 15% from FY 2023). Profit margin: 15% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 13% per year.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.10 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 December 2024. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.6%).
お知らせ • Nov 11Advent Pharma Ltd. to Report Q1, 2025 Results on Nov 13, 2024Advent Pharma Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 06New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 138% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (138% cash payout ratio). Revenue is less than US$5m (৳569m revenue, or US$4.7m). Market cap is less than US$100m (৳1.65b market cap, or US$13.8m).
Declared Dividend • Oct 31Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 21st November 2024 Payment date: 22nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (20% earnings payout ratio) but not covered by cash flows (138% cash payout ratio). The dividend has increased by an average of 5.2% per year over the past 6 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.
お知らせ • Oct 30Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024, at 12:00 Central Asia Standard Time.
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ৳19.80, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 31% over the past three years.
お知らせ • Oct 21Advent Pharma Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Advent Pharma Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.90, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.
Buy Or Sell Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ৳19.90. The fair value is estimated to be ৳25.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.
お知らせ • Sep 03Advent Pharma Ltd. Appoints Md. Delwar Hossen as Company SecretaryAdvent Pharma Ltd. announced that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company.
Buy Or Sell Opportunity • Jun 13Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ৳25.40. The fair value is estimated to be ৳21.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%.
New Risk • May 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳564m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 12% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳564m revenue, or US$4.8m). Market cap is less than US$100m (৳2.81b market cap, or US$24.0m).
Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳26.90, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 48% over the past three years.
お知らせ • Apr 30Advent Pharma Ltd. to Report Q3, 2024 Results on Apr 29, 2024Advent Pharma Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: ৳0.27 (vs ৳0.28 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.27 (down from ৳0.28 in 2Q 2023). Revenue: ৳137.1m (up 4.1% from 2Q 2023). Net income: ৳25.1m (down 5.5% from 2Q 2023). Profit margin: 18% (down from 20% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.
お知らせ • Jan 24Advent Pharma Ltd. to Report Q2, 2023 Results on Jan 30, 2024Advent Pharma Ltd. announced that they will report Q2, 2023 results on Jan 30, 2024
New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (৳2.29b market cap, or US$20.9m).
Valuation Update With 7 Day Price Move • Dec 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳27.00, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 24% over the past three years.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per share at 0.9% yieldEligible shareholders must have bought the stock before 21 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).
お知らせ • Nov 13Advent Pharma Ltd. to Report Q1, 2024 Results on Nov 14, 2023Advent Pharma Ltd. announced that they will report Q1, 2024 results on Nov 14, 2023
お知らせ • Oct 31+ 1 more updateAdvent Pharma Ltd., Annual General Meeting, Dec 28, 2023Advent Pharma Ltd., Annual General Meeting, Dec 28, 2023, at 12:00 Bangladesh Standard Time.
お知らせ • Oct 20Advent Pharma Ltd. to Report Fiscal Year 2023 Results on Oct 28, 2023Advent Pharma Ltd. announced that they will report fiscal year 2023 results on Oct 28, 2023
Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.29 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.28 (down from ৳0.29 in 3Q 2022). Revenue: ৳149.4m (up 3.0% from 3Q 2022). Net income: ৳26.5m (down 3.4% from 3Q 2022). Profit margin: 18% (down from 19% in 3Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 15Second quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.28 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.28 (up from ৳0.28 in 2Q 2022). Revenue: ৳131.7m (up 4.4% from 2Q 2022). Net income: ৳26.6m (up 2.2% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳23.30, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 41% over the past three years.
Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 01Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Advent Pharma Ltd. has recommended 2% cash dividend only for general shareholders (Excluding Sponsors and Directors) for the year ended June 30, 2022.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ৳24.50, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Aug 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 11% over the past three years.
Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 9.3% over the past three years.
Upcoming Dividend • Nov 14Upcoming dividend of ৳0.20 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 16 January 2022. Trailing yield: 0.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳28.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 3.2% over the past three years.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ৳32.20, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years.
Reported Earnings • Sep 10Third quarter 2021 earnings released: EPS ৳0.23 (vs ৳0.23 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ৳125.2m (down 14% from 3Q 2020). Net income: ৳20.8m (up 1.4% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳26.30, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 2.9% over the past three years.
Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳23.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years.
Is New 90 Day High Low • Jan 07New 90-day high: ৳23.70The company is up 14% from its price of ৳20.73 on 08 October 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 20% over the same period.
Reported Earnings • Dec 24Third quarter 2020 earnings released: EPS ৳0.23The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳144.8m (down 9.2% from 3Q 2019). Net income: ৳20.5m (down 54% from 3Q 2019). Profit margin: 14% (down from 28% in 3Q 2019). The decrease in margin was primarily driven by lower revenue.
お知らせ • Jul 07Advent Pharma Ltd. to Report Q3, 2020 Results on Jun 24, 2020Advent Pharma Ltd. announced that they will report Q3, 2020 results on Jun 24, 2020